NCT06412224View on ClinicalTrials.gov

The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2028

Conditions
PDR - Proliferative Diabetic Retinopathy
Interventions
DRUG

RRG001

Administered by subretinal injection. Dosage form: injection.

Trial Locations (1)

Unknown

RECRUITING

Tianjin medical university eye hospital, Tianjin

All Listed Sponsors
collaborator

Shanghai Refreshgene Technology Co., Ltd.

INDUSTRY

lead

Li Xiaorong

OTHER